Patents by Inventor Marcus Geese

Marcus Geese has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CASEIN KINASE 1 INHIBITORS FOR USE IN THE TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION SUCH AS MUSCULAR DYSTROPHY AND CANCER
    Publication number: 20220226340
    Abstract: The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds.
    Type: Application
    Filed: June 12, 2020
    Publication date: July 21, 2022
    Applicant: Facio Intellectual Property B.V.
    Inventors: Joris De Maeyer, Marcus Geese, Sebastian Monecke, Rolf Hirsch, Pui Leng Loke
  • Compounds for treatment of diseases related to DUX4 expression
    Publication number: 20220226318
    Abstract: The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies, wherein the disease is facioscapulohumeral muscular dystrophy (FSHD). It also relates to use of such compounds, or to methods of use of such compounds.
    Type: Application
    Filed: January 13, 2022
    Publication date: July 21, 2022
    Applicant: Facio Intellectual Property B.V.
    Inventors: Joris De Maeyer, Marcus Geese, Martin Schneider, Sebastian Monecke, Alexander Kaever, Monika Ermann, Timothy Robin James
  • Compounds for treatment of diseases related to DUX4 expression
    Publication number: 20210177847
    Abstract: The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds.
    Type: Application
    Filed: December 13, 2018
    Publication date: June 17, 2021
    Applicant: Facio Intellectual Property B.V.
    Inventors: Joris De Maeyer, Marcus Geese, Martin Schneider, Sebastian Monecke, Alexander Kaever, Monika Ermann, Timothy Robin James
  • Compounds for treatment of diseases related to DUX4 expression
    Patent number: 10973820
    Abstract: The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies, wherein the disease is facioscapulohumeral muscular dystrophy (FSHD). It also relates to use of such compounds, or to methods of use of such compounds.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: April 13, 2021
    Assignee: Facio Intellectual Property B.V.
    Inventors: Joris de Maeyer, Marcus Geese, Martin Schneider, Sebastian Monecke, Alexander Kaever, Monika Ermann, Timothy Robin James
  • Compounds for treatment of diseases related to DUX4 expression
    Publication number: 20190175596
    Abstract: The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies, wherein the disease is facioscapulohumeral muscular dystrophy (FSHD). It also relates to use of such compounds, or to methods of use of such compounds.
    Type: Application
    Filed: December 12, 2018
    Publication date: June 13, 2019
    Applicant: Facio Intellectual Property B.V.
    Inventors: Joris de Maeyer, Marcus Geese, Martin Schneider, Sebastian Monecke, Alexander Kaever, Monika Ermann, Timothy Robin James
  • NOVEL NEURTURIN CONJUGATES FOR PHARMACEUTICAL USE
    Publication number: 20160060317
    Abstract: The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.
    Type: Application
    Filed: April 8, 2015
    Publication date: March 3, 2016
    Inventors: Matthias Austen, Marcus Geese, Rainer Mussmann, Friedrich Harder, Thomas Siegmund, Martin Schneider
  • Neurturin conjugates for pharmaceutical use
    Patent number: 9029323
    Abstract: The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.
    Type: Grant
    Filed: May 5, 2010
    Date of Patent: May 12, 2015
    Assignee: Evotec International GmbH
    Inventors: Matthias Austen, Marcus Geese, Rainer Mussmann, Friedrich Harder, Thomas Siegmund, Martin Schneider
  • NOVEL NEURTURIN CONJUGATES FOR PHARMACEUTICAL USE
    Publication number: 20130231283
    Abstract: The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.
    Type: Application
    Filed: February 1, 2013
    Publication date: September 5, 2013
    Applicant: DeveloGen Aktiengesellschaft
    Inventors: Matthias Austen, Marcus Geese, Rainer Mussmann, Friedrich Harder, Thomas Siegmund, Martin Schneider
  • Use of azapaullones for preventing and treating pancreatic autoimmune disorders
    Patent number: 7968535
    Abstract: This invention relates to the use of azapaullones, particularly in combination with immunomodulating agents, in the prevention, and/or treatment of pancreatic autoimmune disorders, e.g. type I diabetes or LADA and neurodegenerative disorders.
    Type: Grant
    Filed: May 4, 2006
    Date of Patent: June 28, 2011
    Assignees: Develogen Atkiengesellschaft, Technische Universitaet Carolo-Wilhelmina Zu Braunschweig
    Inventors: Rainer Mussmann, Conrad Peter Kunick, Hendrik Stukenbrock, Marcus Geese, Simone Kegel, Ulrike Burk
  • NOVEL NEURTURIN CONJUGATES FOR PHARMACEUTICAL USE
    Publication number: 20110003741
    Abstract: The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.
    Type: Application
    Filed: May 5, 2010
    Publication date: January 6, 2011
    Applicant: DEVELOGEN AKTIENGESELLSCHAFT
    Inventors: Matthias Austen, Marcus Geese, Rainer Mussmann, Friedrich Harder, Thomas Siegmund, Martin Schneider
  • USE OF MNK INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
    Publication number: 20100247517
    Abstract: The present invention relates to the use of modulators of the kinase activity of Mnk1 and/or Mnk2 the diagnosis, alleviation, treatment and/or prevention of a tauopathy. Particularly, the present invention relates to the use of a modulator of Mnk1 and/or Mnk2 kinase for the diagnosis, alleviation, treatment and/or prevention of Alzheimer's disease. Preferably, the compounds are condensed pyrimidines.
    Type: Application
    Filed: November 21, 2008
    Publication date: September 30, 2010
    Applicant: Boehringer Ingelheim Internationational GmbH
    Inventors: Matthias Austen, Marcus Geese, Martin Schneider
  • Use of Azapaullones For Preventing and Treating Pancreatic Autoimmune Disorders
    Publication number: 20080287423
    Abstract: This invention relates to the use of azapaullones, particularly in combination with immunomodulating agents, in the prevention, and/or treatment of pancreatic autoimmune disorders, e.g. type I diabetes or LADA and neurodegenerative disorders.
    Type: Application
    Filed: May 4, 2006
    Publication date: November 20, 2008
    Inventors: Rainer Mussmann, Conrad Peter Kunick, Hendrik Stukenbrock, Marcus Geese, Simone Kegel, Ulrike Burk
  • Cg3842 homologous proteins involved in the regulation of energy homeostasis
    Publication number: 20050107317
    Abstract: The present invention discloses CG3842 or SCAD homologous proteins regulating the energy homeostasis and the metabolism of triglycerides, and polynucleotides, which identify and encode the proteins disclosed in this invention. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of metabolic diseases and disorders.
    Type: Application
    Filed: March 7, 2003
    Publication date: May 19, 2005
    Inventors: Marcus Geese, Martin Meise, Bronner Gunter